PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23533666-6 2013 IL-10 secreted in response to zymosan was able to promote STAT3 phosphorylation via an autocrine feedback loop. Zymosan 30-37 interleukin 10 Mus musculus 0-5 22760540-0 2013 IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Zymosan 87-94 interleukin 10 Mus musculus 0-4 25114223-4 2014 Toward this end, we screened a library of well-annotated kinase inhibitors for compounds that enhance production of IL-10 by murine bone-marrow-derived DCs stimulated with the yeast cell wall preparation zymosan. Zymosan 204-211 interleukin 10 Mus musculus 116-121 23675534-7 2013 We found that the number of Treg cells and the levels of the Treg cell-related transcription factor (Foxp3) and cytokines (IL-10) in the zymosan-treated group significantly decreased on day 1 and day 2 and significantly increased on day 5 compared with the NS-treated group. Zymosan 137-144 interleukin 10 Mus musculus 123-128 23533666-8 2013 We further show that the reduction in IL-10 production in the MSK1/2 macrophages results in increased secretion of IL-12p40 in response to zymosan relative to wild type controls. Zymosan 139-146 interleukin 10 Mus musculus 38-43 23533666-11 2013 The expression of these makers was further reinforced by the high level of IL-10 secreted in response to zymosan stimulation. Zymosan 105-112 interleukin 10 Mus musculus 75-80 18516709-9 2008 RESULTS: During zymosan peritonitis, there was a decreased production of IFN-alpha (p = 0.03) and IL-10 (p = 0.03) and elevated synthesis of NO (p = 0.0001) in KO mice compared with WT controls. Zymosan 16-23 interleukin 10 Mus musculus 98-103 22443189-3 2012 In the present study, we observed that macrophages from infant mice produced decreased levels of TNF-alpha and IL-6, but increased IL-10 after stimulation with toll-like receptor 2 (TLR2) agonist zymosan. Zymosan 196-203 interleukin 10 Mus musculus 131-136 22268994-0 2012 Natural killer T cells suppress zymosan A-mediated granuloma formation in the liver by modulating interferon-gamma and interleukin-10. Zymosan 32-41 interleukin 10 Mus musculus 119-133 22268994-6 2012 Also, zymosan A increased interleukin-10 production in WT mice, which suppresses IFN-gamma production. Zymosan 6-15 interleukin 10 Mus musculus 26-40 19481591-5 2009 Glaucine succeeded to enhance LPS and zymosan-induced IL-10 production. Zymosan 38-45 interleukin 10 Mus musculus 54-59 19050249-4 2008 Exposure of APCs of NOD mice to zymosan, a fungal cell wall component that interacts with TLR2 and dectin 1, resulted in the release of significant amounts of IL-10, TGF-beta1, IL-2, and TNF-alpha. Zymosan 32-39 interleukin 10 Mus musculus 159-164 19050249-8 2008 Further, activation by anti-CD3-Ab induced larger amounts of TGF-beta1 and/or IL-10 production by CD4(+)CD25(+) and CD4(+)CD25(-) T cells from zymosan-treated mice. Zymosan 143-150 interleukin 10 Mus musculus 78-83 18160304-0 2008 Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Zymosan 92-99 interleukin 10 Mus musculus 22-36 18160304-2 2008 Here we investigate the effects of IL-10 gene deletion on the acute phase of the multiple organ dysfunction syndrome (MODS) caused by zymosan in the mouse. Zymosan 134-141 interleukin 10 Mus musculus 35-40 18160304-9 2008 With regard to organ injury, absence of IL-10 enhanced the renal, hepatocellular and pancreatic dysfunction caused by zymosan administration. Zymosan 118-125 interleukin 10 Mus musculus 40-45 18160304-11 2008 Therefore, this study demonstrates that the absence of endogenous IL-10 enhances the MODS induced by zymosan in mice. Zymosan 101-108 interleukin 10 Mus musculus 66-71 17238832-3 2006 IL-10 induction was TLR ligand selective, in that CpG DNA, imidazoquinolin, peptidoglycan, and zymosan but not lipopolysaccharide (LPS) and poly I:C led to IL-10 production. Zymosan 95-102 interleukin 10 Mus musculus 0-5 17458858-0 2007 Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Zymosan 87-94 interleukin 10 Mus musculus 48-53 17458858-1 2007 Zymosan is a particulate yeast preparation that elicits high levels of IL-2 and IL-10 from dendritic cells (DC) and engages multiple innate receptors, including the Syk-coupled receptor dectin-1 and the MyD88-coupled receptor TLR2. Zymosan 0-7 interleukin 10 Mus musculus 80-85 17458858-2 2007 Here, we show that induction of IL-2 and IL-10 by zymosan requires activation of ERK MAP kinase in murine DC. Zymosan 50-57 interleukin 10 Mus musculus 41-46 25377877-5 2015 Ag-specific T cells that are activated using zymosan-exposed dendritic cells (DCs) expressed Foxp3 and produced large amounts of IL-10, TGF-beta1, and IL-17. Zymosan 45-52 interleukin 10 Mus musculus 129-134 28702731-2 2017 Increase in the concentration of corticosterone was independent of the blockade of opioid receptors, whereas the zymosan-induced increase in the production of oxygen radicals and activation of the spontaneous production of IL-10 was blocked in mice by naloxone. Zymosan 113-120 interleukin 10 Mus musculus 223-228 16543948-3 2006 First, zymosan induces DCs to secrete abundant IL-10 but little IL-6 and IL-12(p70). Zymosan 7-14 interleukin 10 Mus musculus 47-52 16543948-7 2006 Consistent with these effects on APCs, injection of zymosan plus OVA into mice results in OVA-specific T cells that secrete little or no Th1 or Th2 cytokines, but secrete robust levels of IL-10, and are unresponsive to challenge with OVA plus adjuvant. Zymosan 52-59 interleukin 10 Mus musculus 188-193 16543948-8 2006 Finally, coinjection of zymosan with OVA plus LPS suppresses the response to OVA via a mechanism dependent on IL-10, TGF-beta, and lack of IL-6. Zymosan 24-31 interleukin 10 Mus musculus 110-115 16543948-9 2006 Together, our data demonstrate that zymosan stimulates IL-10+ IL-12(p70)- IL-6low regulatory DCs and TGF-beta+ macrophages to induce immunological tolerance. Zymosan 36-43 interleukin 10 Mus musculus 55-60 12951065-5 2003 It also augmented IL-10 production in the presence of zymosan, a yeast cell wall component. Zymosan 54-61 interleukin 10 Mus musculus 18-23 10479408-0 1999 Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. Zymosan 48-55 interleukin 10 Mus musculus 0-14 10479408-7 1999 IL-10 improves survival and clinical condition and also reduces organ damage, but only at the highest dose used and only when started simultaneously with the administration of zymosan. Zymosan 176-183 interleukin 10 Mus musculus 0-5 10479408-10 1999 The anti-inflammatory cytokine IL-10 is able to attenuate the development of MODS in this model, but only when given simultaneously with zymosan, and in high dosages. Zymosan 137-144 interleukin 10 Mus musculus 31-36 9893055-4 1998 Injection of zymosan also induced a time-dependent increase in the production of the anti-inflammatory cytokine interleukin-10 (IL-10) in the peritoneal cavity. Zymosan 13-20 interleukin 10 Mus musculus 112-126 9893055-4 1998 Injection of zymosan also induced a time-dependent increase in the production of the anti-inflammatory cytokine interleukin-10 (IL-10) in the peritoneal cavity. Zymosan 13-20 interleukin 10 Mus musculus 128-133 27709605-5 2017 Unlike lipopolysaccharide (LPS), zymosan induced IL-10 and phosphorylated Y705-STAT3 to a similar extent in Irf3 and Ifnar1 knockout and wild-type mice. Zymosan 33-40 interleukin 10 Mus musculus 49-54